MAXONA PHARMACEUTICALS EMERGES FROM STEALTH AS IT ACHIEVES MILESTONE IN DEVELOPMENT OF FIRST-TO-MARKET CANDIDATE MAX-001
MAXONA Pharmaceuticals today announced that it has emerged from stealth with the completion of the U.S. Phase 1 clinical ...
openaccessgovernment12h
Process intensification: A game changer for the pharma market
Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...
Moleculin Announces First European Approval for Phase 3 AML Trial
HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...